Preview complete
The prescreener preview is complete. You may now close the preview.
A Phase 1 Study of IL-15 Superagonist (N-803) and Broadly Neutralizing Antibodies to Induce HIV-1 Control
Recruiting
18-70 years
All
Phase
1
3 participants needed
1 Location
Brief description of study
This study will investigate whether N-803, a new experimental drug that stimulates the immune system, is safe and tolerable when given alone and in combination with two new experimental drugs that are antibodies (natural proteins that the body makes in response to an infection) to HIV (the virus that causes AIDS), VRC07-523LS and 10-1074.
Detailed description of study
Study duration: 100-112 weeks
Participants must be willing to participate in analytic treatment interruption (ATI)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: HIV,antiretroviral,analytic treatment interruption
-
Age: Between 18 Years - 70 Years
-
Gender: All
Individuals living with HIV on ART with a viral load <50 copies/mL for at least 96 weeks.
Lowest CD4 count > 200 cells/mm3
Updated on
01 Aug 2024.
Study ID: 848907
Pre-Screener
